ArticleInnere Medizin (Heidelberg, Germany)2025
[InspeCKD: an analysis of the prevalence, diagnosis, and treatment of chronic kidney disease : Data from at-risk patients in German primary care].
Article in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glomerular Filtration Rate, Albuminuria, and Reported Kidney Disease in Comparison: Results From the German National Cohort (NAKO).Deutsches Arzteblatt international · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with hypertension, diabetes mellitus (DM) and/or cardiovascular disease (CVD) have a higher risk of developing chronic kidney disease (CKD) and should therefore be closely monitored. Early diagnosis and guideline-directed disease management can reduce the risk of kidney failure and cardiorenal complications.
objectivesThe aim of this retrospective cross-sectional study was to gain a better understanding of the prevalence, diagnosis, and guideline-directed treatment of CKD in patients at risk for CKD in German general practitioner (GP) practices. MATERIALS AND
methodsA total of 1244 GPs provided fully anonymized electronic data sets for the analysis (study period 06/2020-06/2023). According to the screening recommendations of Kidney Disease: Improving Global Outcomes (KDIGO), adults with hypertension and/or DM and/or CVD with a documented observation period of at least 1 year were included in the study.
resultsThe prevalence of CKD was 18.8% (n = 24,179), of which 16.5% of at-risk patients (n = 3986) had a documented diagnosis of CKD according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10). Thus, 83.5% (n = 20.193) of patients at risk remained undiagnosed. Within 6 months of diagnosis, 9.7% (n = 1740) of ICD-10-diagnosed CKD patients were treated with a renin-angiotensin system inhibitor (RASi) in combination with a sodium-glucose cotransporter‑2 inhibitor (SGLT2i).
conclusionThe results highlight substantial gaps in early diagnosis and treatment of CKD in Germany. There is an urgent need for greater awareness among GPs of this under-recognized disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.